Abstract
Objective: To compare the efficacy, safety and tolerability of valsartan to an angiotensin-converting enzyme (ACE) inhibitor, lisinopril, and placebo in patients with mild-to-moderate essential hypertension.Design: A total of 734 men and women were randomised in this multicentre, double-blind, optional titration, parallel group trial. Volunteers received valsartan 80 mg (n = 364), lisinopril 10 mg (n = 187) or placebo (n = 183) daily for 4 weeks, with subsequent titration of dose depending on response to treatment (valsartan 80 mg titrated to valsartan 160 mg once daily or valsartan 80 mg twice daily, lisinopril 10 mg titrated to lisonopril 20 mg once daily). Patients were assessed at 4, 8 and 12 weeks.Main outcome measures: The primary variable was change from baseline in mean sitting diastolic blood pressure (SDBP). Other efficacy variables included sitting systolic blood pressure (SSBP) and percentage of ‘successful’ responders (SDBP <90 mm hg or ⩾10 mm hg reduction from baseline).Results: All active treatment groups were shown to demonstrate significant reductions in SDBP compared to placebo at endpoint of therapy (least mean square reduction from baseline: valsartan 80/160 mg: −5.25 mm Hg (CI −7.17, −3.34, P < 0.001); valsartan 80/80 mg twice daily: −5.63 mm hg (ci −7.51,−3.75, P < 0.001); lisinopril 10/20 mg: −6.93 mm hg, (ci −8.81, −5.05, P < 0.001). there were no statistically significant differences between the active treatment groups at endpoint of therapy. in patients requiring titration to a higher dose (placebo n = 142, valsartan 80/80 twice daily n = 124, valsartan 80/160 n = 114, lisinopril 10/20 n = 120), there were no significant treatment differences between valsartan 160 mg given as a single daily dose or as 80 mg twice daily (P = 0.658). Both valsartan and lisinopril produced similarly high percentages of ‘successful’ responders at endpoint of therapy. A somewhat higher frequency of drug related cough was observed in lisinopril treated patients (8%) compared to valsartan (1.1%) or placebo (0.5%).Conclusions: Valsartan 80 mg daily, with titration to 160 mg daily as required, provides similar antihypertensive efficacy to lisinopril 10 mg daily with titration to 20 mg daily. Valsartan provides a new antihypertensive agent with comparable efficacy to lisinopril and appears to be associated with a reduced incidence of cough.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 digital issues and online access to articles
$119.00 per year
only $9.92 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Black, H., Graff, A., Shute, D. et al. Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: efficacy, tolerability and safety compared to an angiotensin-converting enzyme inhibitor, lisinopril. J Hum Hypertens 11, 483–489 (1997). https://doi.org/10.1038/sj.jhh.1000482
Received:
Revised:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/sj.jhh.1000482
Keywords
This article is cited by
-
Adverse effects and non-adherence to antihypertensive medications in University of Gondar Comprehensive Specialized Hospital
Clinical Hypertension (2019)
-
Updated Report on Comparative Effectiveness of ACE inhibitors, ARBs, and Direct Renin Inhibitors for Patients with Essential Hypertension: Much More Data, Little New Information
Journal of General Internal Medicine (2012)
-
Efficacy of Angiotensin Receptor Blockers in Cardiovascular Disease
Cardiovascular Drugs and Therapy (2006)
-
Therapeutic trials comparing angiotensin converting enzyme inhibitors and Angiotensin II receptor blockers
Current Hypertension Reports (2000)